Hilton Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-62,269
Closed -$8.89M 184
2024
Q2
$8.89M Buy
62,269
+3,218
+5% +$426K 0.75% 41
2024
Q1
$7.58M Sell
59,051
-120
-0.2% -$14.3K 0.68% 43
2023
Q4
$6.12M Buy
59,171
+12
+0% +$1.19K 0.66% 42
2023
Q3
$5.38M Sell
59,159
-2,017
-3% -$178K 0.72% 38
2023
Q2
$4.95M Buy
+61,176
New +$5M 0.59% 43

Other funds holding NVO

Hilton Capital Management's NVO Position: Q3 2024 in Review

Hilton Capital Management sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 62,269 shares — an estimated $8.89M sold.

Hilton Capital Management first reported a position in NVO in Q2 2023 and held it in 5 quarters. The position peaked at $8.89M in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Hilton Capital Management reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Hilton Capital Management sold 62,269 Novo Nordisk shares in Q3 2024, an estimated $8.89M.
  • Hilton Capital Management first reported a position in Novo Nordisk in Q2 2023 and held it in 5 quarters.
  • Hilton Capital Management's Novo Nordisk position peaked at $8.89M in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Hilton Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.